Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.13 USD | +6.16% | +35.38% | +23.84% |
04-30 | North American Morning Briefing : More Earnings -2- | DJ |
04-29 | Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 | MT |
Business Summary
Number of employees: 1,022
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule and Gene Therapeutics
100.0
%
| 699 | 100.0 % | 938 | 100.0 % | +34.20% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
56.7
%
| 499 | 71.3 % | 532 | 56.7 % | +6.64% |
Non-United States
43.3
%
| 200 | 28.7 % | 406 | 43.3 % | +102.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 52 | 30/09/19 |
Pierre Gravier
DFI | Director of Finance/CFO | 39 | 12/07/23 |
Ellen Welch
CTO | Chief Tech/Sci/R&D Officer | - | - |
Neil Almstead
CTO | Chief Tech/Sci/R&D Officer | 57 | 31/12/99 |
Kylie O'Keefe
IRC | Investor Relations Contact | - | 30/04/18 |
Human Resources Officer | - | 31/12/17 | |
Timothy Dyer
SEC | Corporate Secretary | - | 31/05/18 |
Marla Weetall
PRN | Corporate Officer/Principal | - | 30/09/02 |
Corporate Officer/Principal | - | - | |
Christine Utter
AUD | Comptroller/Controller/Auditor | 46 | 31/12/09 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Steele
BRD | Director/Board Member | 79 | 14/06/15 |
Chairman | 72 | 31/07/01 | |
David Southwell
BRD | Director/Board Member | 63 | 30/11/05 |
Allan Jacobson
FOU | Founder | 78 | 30/03/98 |
Emma Reeve
BRD | Director/Board Member | 63 | 17/12/18 |
Jerome Zeldis
BRD | Director/Board Member | 74 | 27/09/12 |
Alethia Young
BRD | Director/Board Member | 45 | 08/06/22 |
Matthew Klein
CEO | Chief Executive Officer | 52 | 30/09/19 |
Mary Smith
BRD | Director/Board Member | 61 | 07/06/21 |
Stephanie Okey
BRD | Director/Board Member | 64 | 17/12/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 76,696,785 | 74,876,839 ( 97.63 %) | 0 | 97.63 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
CLEARPOINT NEURO, INC. 3.32% | 894,578 | 3.32% | 6,083,130 $ |
Company contact information
PTC Therapeutics, Inc.
100 Corporate Court
07080-2449, South Plainfield
+908 222 7000
http://www.ptcbio.comGroup companies
Name | Category and Sector |
---|---|
PTC Therapeutics International Ltd.
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.84% | 2.62B | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+2.13% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- PTCT Stock
- Company PTC Therapeutics, Inc.